Bahashwan Salem, Alsaadi Mohammed, Barefah Ahmed, Almahdi Hadiah, Alahwal Hatem, Almohammadi Abdullah, Radhwi Osman, Daous Yara, Idrees Sherif, Almehdar Hussien, Qadri Ishtiaq
Hematology Department, Faculty of Medicine, King Abdulaziz University, Jeddah, KSA.
Hematology Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, KSA.
J Taibah Univ Med Sci. 2024 May 10;19(3):619-627. doi: 10.1016/j.jtumed.2024.04.010. eCollection 2024 Jun.
Lymphoma ranks fifth in prevalence among common cancer types worldwide. This lymphatic system cancer arises from T or B cells. Diffuse large B cell lymphomas (DLBCLs) are associated with most non-Hodgkin lymphomas. Non-coding microRNAs (miRNAs) greatly affect gene expression. A single miRNA can target numerous genes, thus largely influencing gene expression networks. MiRNAs can act as oncogenes or tumor suppressors in controlling DLBCL progression. This study investigated the roles of miRNAs in patients with DLBCL through next-generation sequencing, which was found to be sensitive, accurate, and robust.
The study involved seven patients with DLBCLs and three controls at a hematology-oncology clinic. MiRNA was extracted from existing formalin-fixed, paraffin-embedded (FFPE) tissue specimens. Illumina next-generation sequencing was used to sequence samples for miRNA profiling.
Samples from patients showed expression of various hsa-mir miRNAs (1248, 3607, 21, 142, 1244, 182, 6516, 766, 1291, 4449, and 181a), whereas those from healthy individuals showed expression of hsa-mir 1248, 3607, 21, 142, and 877. Hsa-mir-877-3p is known to target multiple genes, and miRNAs such as hsa-mir-877-3p, hsa-mir-1291, and hsa-mir-181a-5p interact primarily with target genes.
MiRNA profiling in FFPE tissues from patients with DLBCL suggested that miRNA levels can distinguish patients with DLBCL from controls, and therefore may provide prognostic or diagnostic biomarkers for DLBCL. Altered genes and miRNAs may also be potential therapeutic targets.
淋巴瘤在全球常见癌症类型中患病率排名第五。这种淋巴系统癌症起源于T细胞或B细胞。弥漫性大B细胞淋巴瘤（DLBCL）与大多数非霍奇金淋巴瘤相关。非编码微小RNA（miRNA）对基因表达有很大影响。单个miRNA可以靶向众多基因，从而在很大程度上影响基因表达网络。miRNA在控制DLBCL进展中可作为癌基因或肿瘤抑制因子。本研究通过新一代测序调查了miRNA在DLBCL患者中的作用，发现该测序灵敏、准确且可靠。
该研究纳入了一家血液肿瘤诊所的7例DLBCL患者和3例对照。从现有的福尔马林固定、石蜡包埋（FFPE）组织标本中提取miRNA。使用Illumina新一代测序对样本进行miRNA谱测序。
患者样本显示出多种hsa-mir miRNA（1248、3607、21、142、1244、182、6516、766、1291、4449和181a）的表达，而健康个体的样本显示出hsa-mir 1248、3607、21、142和877的表达。已知hsa-mir-877-3p可靶向多个基因，并且hsa-mir-877-3p、hsa-mir-1291和hsa-mir-181a-5p等miRNA主要与靶基因相互作用。
DLBCL患者FFPE组织中的miRNA谱表明，miRNA水平可区分DLBCL患者与对照，因此可能为DLBCL提供预后或诊断生物标志物。基因和miRNA的改变也可能是潜在的治疗靶点。
